Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$78.00 | Sdrrctk | Yxtmscdh |
Baxter Expects More Weakness on Bottom Line in 2023
Business Strategy and Outlook
Following the spinoff of Baxalta in mid-2015, Baxter's new management team has focused on increasing efficiencies and innovating in medical products. That focus has resulted in much-improved profitability and cash flow generation since then. At its 2022 investor, the company highlighted a goal for mid-single-digit sales growth primarily through new product launches and for double-digit adjusted earnings per share and free cash flow growth compounded annually. Acquisitions, like the recent combination with Hillrom (medical equipment like hospital beds with digital connection capabilities), could add to those prospects, if executed properly.